These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11166451)

  • 1. Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds.
    Guest I; Uetrecht J
    Exp Hematol; 2001 Feb; 29(2):123-37. PubMed ID: 11166451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical status of the new cytoprotective agent, amifostine.
    Kalaycioglu M; Bukowski R
    Oncology (Williston Park); 1994 Jul; 8(7):15-6, 19-20, 23. PubMed ID: 7522504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
    Blumenthal RD; Lew W; Juweid M; Alisauskas R; Ying Z; Goldenberg DM
    Cancer; 2000 Jan; 88(2):333-43. PubMed ID: 10640965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
    Capizzi RL; Scheffler BJ; Schein PS
    Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs and the bone marrow.
    Treleaven J; Barrett J
    Br J Hosp Med; 1990 Oct; 44(4):245-50. PubMed ID: 2249099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amifostine protects bone marrow from benzene-induced hematotoxicity in mice.
    Yu K; Yang KY; Ren XZ; Chen Y; Liu XH
    Int J Toxicol; 2007; 26(4):315-23. PubMed ID: 17661222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic complications of cancer chemotherapy.
    Hoagland HC
    Semin Oncol; 1982 Mar; 9(1):95-102. PubMed ID: 7071611
    [No Abstract]   [Full Text] [Related]  

  • 8. Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
    Budd GT; Ganapathi R; Wood L; Snyder J; McLain D; Bukowski RM
    Semin Oncol; 1999 Apr; 26(2 Suppl 7):41-50. PubMed ID: 10348260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine and chemotherapy-related thrombocytopenia.
    Budd GT
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):49-52. PubMed ID: 8783667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
    Kalechman Y; Rushkin G; Nerubay J; Albeck M; Sredni B
    Exp Hematol; 1995 Dec; 23(13):1358-66. PubMed ID: 7498364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic and microenvironmental alterations in bone marrow associated with ROS in experimental aplastic anemia.
    Chatterjee R; Law S
    Eur J Cell Biol; 2018 Jan; 97(1):32-43. PubMed ID: 29173808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action.
    Kalechman Y; Shani A; Sotnik-Barkai I; Albeck M; Sredni B
    Cancer Res; 1993 Dec; 53(24):5962-9. PubMed ID: 8261410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.
    Paukovits WR; Moser MH; Binder KA; Paukovits JB
    Cancer Treat Rev; 1990 Sep; 17(2-3):347-54. PubMed ID: 2272050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Boston Collaborative Drug Surveillance Program.
    JAMA; 1974 Mar; 227(9):1036-40. PubMed ID: 4405931
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative effects of amifostine (Ethyol) on normal hematopoietic stem cells versus human leukemic cells during ex vivo purging in autologous bone marrow transplants.
    Douay L; Hu C; Giarratana MC; Gorin NC
    Semin Oncol; 1994 Oct; 21(5 Suppl 11):16-20. PubMed ID: 7973773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide.
    Sredni B; Albeck M; Tichler T; Shani A; Shapira J; Bruderman I; Catane R; Kaufman B; Kalechman Y
    J Clin Oncol; 1995 Sep; 13(9):2342-53. PubMed ID: 7666093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The membrane-bound isoform of stem cell factor synergizes with soluble flt3 ligand in supporting early hematopoietic cells in long-term cultures of normal and aplastic anemia bone marrow.
    Slanicka Krieger M; Nissen C; Manz CY; Toksoz D; Lyman SD; Wodnar-Filipowicz A
    Exp Hematol; 1998 May; 26(5):365-73. PubMed ID: 9590652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic reactions to carbonic anhydrase inhibitors.
    Fraunfelder FT; Meyer SM; Bagby GC; Dreis MW
    Am J Ophthalmol; 1985 Jul; 100(1):79-81. PubMed ID: 4014383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects.
    Douay L; Hu C; Giarratana MC; Gorin NC
    Eur J Cancer; 1995; 31A Suppl 1():S14-6. PubMed ID: 7577094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic insult oriented mitochondrial instability and proliferative hindrance in the bone marrow of aplastic mice including stem/progenitor population.
    Chatterjee R; Law S
    Pathol Res Pract; 2019 Apr; 215(4):784-793. PubMed ID: 30683472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.